Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.
Angela GengeGary L PatteeGen SobueMasashi AokiHiide YoshinoPhilippe CouratierChristian LunettaSusanne PetriDaniel SelnessSachin BidaniManabu HiraiTakeshi SakataAlejandro SalahStephen AppleArt WamilAlexander KalinCarlayne E JacksonPublished in: Muscle & nerve (2022)
This study indicated that oral edaravone was well tolerated during 48 weeks of treatment, with no new safety concerns identified. This article is protected by copyright. All rights reserved.